Structural biology of the tumor suppressor p53 and cancer-associated mutants

被引:82
作者
Joerger, Andreas C. [1 ]
Fersht, Alan R. [1 ]
机构
[1] MRC, Ctr Prot Engn, Cambridge CB2 2QH, England
来源
ADVANCES IN CANCER RESEARCH, VOL 97 | 2007年 / 97卷
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0065-230X(06)97001-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor suppressor protein p53 is a transcription factor that plays a key role in the prevention of cancer development. In response to oncogenic or other stresses, the p53 protein is activated and regulates the expression of a variety of target genes, resulting in cell cycle arrest, senescence, or apoptosis. Mutation of the p53 gene is the most common genetic alteration in human cancer, affecting more than 50% of human tumors. Most of these mutations inactivate the DNA-binding domain of the protein. In this chapter, we describe the structure of the wild-type p53 protein and present structural and functional data that provide the molecular basis for understanding the effects of common cancer mutations. Further, we assess novel therapeutic strategies that aim to rescue the function of p53 cancer mutants. (c) 2007 Elsevier Inc.
引用
收藏
页码:1 / +
页数:26
相关论文
共 84 条
[1]   Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains [J].
Ang, Hwee Ching ;
Joerger, Andreas C. ;
Mayer, Sebastian ;
Fersht, Alan R. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (31) :21934-21941
[2]   4 P53 DNA-BINDING DOMAIN PEPTIDES BIND NATURAL P53-RESPONSE ELEMENTS AND BEND THE DNA [J].
BALAGURUMOORTHY, P ;
SAKAMOTO, H ;
LEWIS, MS ;
ZAMBRANO, N ;
CLORE, GM ;
GRONENBORN, AM ;
APPELLA, E ;
HARRINGTON, RE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (19) :8591-8595
[3]   A global suppressor motif for p53 cancer mutants [J].
Baroni, TE ;
Wang, T ;
Qian, H ;
Dearth, LR ;
Truong, LN ;
Zeng, J ;
Denes, AE ;
Chen, SW ;
Brachmann, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :4930-4935
[4]   Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations [J].
Brachmann, RK ;
Yu, KX ;
Eby, Y ;
Pavletich, NP ;
Boeke, JD .
EMBO JOURNAL, 1998, 17 (07) :1847-1859
[5]   Some p53-binding proteins that can function as arbiters of life and death [J].
Braithwaite, A. W. ;
Del Sal, G. ;
Lu, X. .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (06) :984-993
[6]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[7]   Thermodynamic stability of wild-type and mutant p53 core domain [J].
Bullock, AN ;
Henckel, J ;
DeDecker, BS ;
Johnson, CM ;
Nikolova, PV ;
Proctor, MR ;
Lane, DP ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14338-14342
[8]   Small molecules that reactivate mutant p53 [J].
Bykov, VJN ;
Selivanova, G ;
Wiman, KG .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (13) :1828-1834
[9]   Solution structure of p53 core domain:: Structural basis for its instability [J].
Cañadillas, JMP ;
Tidow, H ;
Freund, SMV ;
Rutherford, TJ ;
Ang, HC ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2109-2114
[10]   How many mutant p53 molecules are needed to inactivate a tetramer? [J].
Chan, WM ;
Siu, WY ;
Lau, A ;
Poon, RYC .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (08) :3536-3551